论文部分内容阅读
目的 回顾性比较分析两种不同治疗方案治疗194例初治儿童急性淋巴细胞白血病(ALL)患儿的疗效.方法 选择2010年6月1日至2013年12月31日于郑州大学第一附属医院小儿内科初诊ALL患儿194例,其中135例采用《儿童急性淋巴细胞白血病临床路径(2010年版)》治疗方案(简称“临床路径组”),59例采用《儿童急性淋巴细胞白血病诊疗建议(第三次修订草案)-2006年》治疗方案(简称“06方案组”),对患儿的临床资料、早期疗效、复发率、3年无病生存率进行分析比较.结果 194例ALL患儿低危型135例,中危型59例;诱导治疗第8天泼尼松实验均反应良好,诱导治疗第15天骨髓完全缓解率(CR)为92.8％,第33天CR率为100％;临床路径组ALL患儿低危型、中危型复发率分别为11.39％ (9/79)、14.28％(8/56),06方案组低危型、中危型复发率为9.09％(3/33)、11.54％(3/26);对于低危型ALL患儿,06方案组的3年无事件生存率(88.7％)稍高于临床路径组(87.2％),但差异未见统计学意义(P＞0.05);对于中危型ALL患儿,06方案组的3年无事件生存率(85.4％)高于临床路径组(78.2％),但差异亦未见统计学意义(P＞0.05).结论 两种方案治疗儿童ALL的疗效差异未见统计学意义.“,”Objective To retrospectively analyze the effects of two different treatment regimens on 194 cases of newly diagnosed childhood acute lymphoblastic leukemia(ALL).Methods The 194 cases of children with newly diagnosed all from June 1,2010 to December 31,2013 in pediatrics ward of the first affiliated hospital of Zhengzhou university,135 cases used the “ clinical pathway of childhood acute lymphoblastic leukemia (2010 edition)” treatment program (referred to as “ clinical pathway group”),while 59 cases used the “ treatment recommendations of childhood acute lymphoblastic leukemia (the third Amendment Bill)-2006” treatment regimens (referred to as “06 program group”)[1].The clinical data,early efficacy,relapse rate,three-year disease-free survival rates of all the ALL patients were analyzed and compared.Results Among the 194 paitents,135 were l9w-risk(LR),59 were medium-risk (MR).All the patients were prednisone good response ALL group in Prednisone test on day 8 th.The CR rate on day 15 was 92.8％ and 100％ on day 33.The reoccur rate of clinical pathway group was 1 1.39％ (9/79) for LR,and 14.28％ (8/56) for MR.While the 06 program group was 9.09％ (3/33) for LR,and 11.54％ (3/26) for MR.For low-risk ALL patients,the 3-year diseasefree survival rate of 06 program group was 88.7％,which was slightly higher than that of the clinical pathway group (87.2％,P ＞ 0.05),but the difference was not statistically significant;for medium-risk ALL patients,the 3-year disease-free survival rate of 06 program group was 85.4％,which was higher than that of the clinical pathway group (78.2％,P ＞0.05),but the difference was also no statistically significant.Conclusions The two regimens have no significant difference in the efficacy on childhood ALL.